+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 3
Age: 12Months - 23Months
All Genders
Healthy Volunteers
ID07505836

Phase 3 Study Comparing Two Group ACYW135 Meningococcal Conjugate Vaccines in Healthy Children Aged 12 to 23 Months to Evaluate Immune Response and Safety

Led by Sinovac Biotech Co., Ltd · Updated on 2026-08-10

1040

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the immune response and safety of an investigational group ACYW135 Meningococcal conjugate vaccine in healthy children aged 12 to 23 months. The study aims to determine if the investigational vaccine produces an immune response that is not worse than that of a licensed control vaccine while monitoring the safety profile in this pediatric population. The trial is a randomized, quadruple-blind phase 3 study sponsored by Sinovac Biotech Co., Ltd. Participants will receive two doses of either the investigational vaccine or the licensed active comparator vaccine according to a 0 and 1-month schedule. Each dose is followed by a 30-minute observation for immediate adverse reactions. The investigational and control vaccines are both group ACYW135 Meningococcal conjugate vaccines but differ in carrier proteins. The trial includes a comparison of immune responses and safety between these two vaccines. During the study, researchers will record local and systemic adverse events for 7 days after each dose and unsolicited adverse events for 30 days post-vaccination using diary cards. Serious adverse events will be monitored for at least six months following completion of the two-dose series. The primary outcomes focus on seroconversion rates and geometric mean titers of meningococcal antibodies 30 days after the second dose. Overall, participants will be followed from the first vaccination through six months after the last dose to assess immune response and safety.

CONDITIONS

Brief Title

Phase Ⅲ Trial of Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 12-23 Months

Research Team

Y

Yi Mo

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here